Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Navitor Pharmaceuticals Inc.

www.navitorpharma.com

Latest From Navitor Pharmaceuticals Inc.

Appointments: Senior Hires At IGM, Cell Medica, Mologen, Navitor, Tenaya, Oncobiologics, Provention Bio And Centrexion

New CEOs have been appointed at Cell Medica, Mologen, Navitor Pharmaceuticals, Tenaya Therapeutics and Oncobiologics, while a new CMO has been recruited to IGM Biosciences, a vice president of clinical development at Provention Bio and a CFO at Centrexion Therapeutics.

Appointments BioPharmaceutical

resTORbio's Age-Related RTI Program Picks Up Further Funding

Clinical studies by resTORbio into age-related immunosenescence attracts investors keen to advance a potential new class of immunotherapy agents.

Financing Infectious Diseases

Where Will CNS Drug Development Go In 2018?

The world's expanding, aging population means diseases of the central nervous system, like Alzheimer's and Parkinson's, are potential blockbuster areas for innovative pharma and biotech companies that are able to navigate clinical studies and get to market. Scrip looks at five emerging trends that are likely to affect the CNS drug development landscape in 2018.

Neurology Business Strategies

Polaris Stays Disciplined For Breakthroughs: An Interview With Alan Crane

The demands of building new biotechs can take their toll, yet Alan Crane wears his 52 years and over two decades of high-risk biotech start-up investing lightly. He's built an exceptional number of companies during his tenure at Polaris, many of which have proved to be among the industry’s more successful emerging ventures.

Leadership Financing
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
  • Pharmaceuticals
  • Therapeutic Areas
  • Immune Disorders
  • Metabolic Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Calorics Pharmaceuticals
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Navitor Pharmaceuticals Inc.
  • Senior Management
  • Thomas E Hughes, PhD, CEO
    Rick Lundberg, VP, Bus., Operations & Fin.
    George P Vlasuk, PhD, Pres. & CSO
  • Contact Info
  • Navitor Pharmaceuticals Inc.
    Phone: (857) 285-4300
    1030 Massachusetts Ave.
    Ste 410
    Cambridge, MA 02139
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register